

February 20, 2017

To,  
Dy. General Manager  
Department of Corporate Services,  
Bombay Stock Exchange Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001.

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,


We have received today a query from the media regarding Glenmark receiving the observations on its Ankleshwar Plant in Gujarat pursuant to the USFDA Audit.

Our response which will be sent to the media agency is given below:

“The API plant at Ankleshwar, India was inspected by the USFDA in December 2016. We received four observations from the FDA via the Form 483. We responded to the observations in January 2017. At this point in time, we have no outstanding items with the USFDA regarding this plant. The Form 483 is an integral part of the inspection process which is used to communicate inspection observations by the USFDA after it audits the manufacturing facility.”

Thanking You.

Yours faithfully,  
For Glenmark Pharmaceuticals Ltd.



Harish Kuber  
Company Secretary & Compliance Officer